Synapsoft logo
AI Insights from Disclosures
Searching...
Kanaph Therapeutics Inc. 0082N0
Searching...

Company Summary

Quarterly Performance Revenue Operating Margin

Market Sentiment

※ Click the graph to view AI analysis information for that month.
Revenue
Consolidated
Separate
Operating Income
Consolidated
Separate
Net Income
Consolidated
Separate

Financials

Excel

No financial data is available for this period.
~
Quarterly
Annual
No data is available for this period.

*Values beyond the fourth decimal place of the unit are displayed as '0/-0'

Financial Indicator Forecast

※ These forecasts are simple AI estimates based on historical data and may differ from actual results.

Company Overview

as of June 2026
Kanaph Therapeutics Inc. is an innovative new drug development company that develops anti-cancer agents and treatments for ophthalmic diseases based on human genome-based drug development technology. The company's core technology lies in discovering novel targets with high unmet medical needs through the analysis of human genome data and disease-specific biological signatures, and developing innovative new drugs of various modalities, including bispecific antibodies, antibody-drug conjugates (ADC), and synthetic new drugs, based on these targets; the core of new drug development lies in selecting the appropriate target for each disease and securing both efficacy and safety simultaneously through drug design optimized for that target.
Representative Director Lee Byeongcheol
Founded February 14, 2019
Corporation Type KOSDAQ
Industry Classification Research and experimental development on medical sciences and pharmacy
Corporate number 11011-7013206
Business number 643-87-01092
Phone Number 02-798-9438
Fax Number 02-792-8638
Company Address 3 Itaewon-ro 55ga-gil, Yongsan-gu, Seoul

Financial Health

Executives

Employees

Shareholders

Industry revenue

Disclosures

Comments

0 / 255

AI Assistant